Pharmacology - Endocrine Cancers Flashcards

(39 cards)

1
Q

What is tamoxifen indicated for?

A
  • Early and metastatic breast cancer, in both pre and post-menopausal women
  • May be useful in chemoprevention of breast cancer in women at high risk
  • Reduces severity of osteoporosis but is not specifically used for osteoporosis due to availability of agents with superior side effect profiles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the mechanism of action of tamoxifen?

A
  • Competitively blocks endogenous estrogen binding to the estrogen receptor in the target
  • Tamoxifen then deactivates the AF2 transcription site (AF1 site is still active), which then serves as a partial blocker to alter estrogen-responsive gene expression → ↓ cancer cell activation & proliferation
  • Exhibits estrogenic (cis-isomer) and anti-estrogenic (trans-isomer) effects
  • Exhibits tissue-specific effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the bioavailability of tamoxifen?

A

~100%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is tamoxifen absorbed?

A

Rapidly and extensively absorbed in intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Does tamoxifen bind to plasma proteins?

A

Yes, >98%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the Vd of tamoxifen?

A

50-60L/kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does tamoxifen distribute in the body?

A

Concentrates well in the breast, uterus, liver, kidney, lung, pancreas, ovaries (uterus cons are 2-3x of circulatory conc, breast conc is 10x)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the elimination half-life of tamoxifen?

A

5-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is tamoxifen metabolised?

A

CYP3A4 -N-desmethyl-tamoxifen
CYP2D6 - 4-OH-tamoxifen

both get metabolised by the other CYP enzyme to endoxifen

Phase 1: Hydroxylation, N-oxidation, dealkylation
Phase 2: Glucuronidation, sulphation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the adverse effects of tamoxifen?

A
  • Hot flashes (non-dose related)
  • Increases risk of endometrial cancer
  • Venous thromboembolic events (DVT)
  • Menstrual irregularities
  • Vaginal bleeding and discharge
  • Nausea, vomiting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the effects of tamoxifen toxicity?

A

Acute neurotoxicity (tremor, hyperreflexia, unsteady gait, dizziness)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the MOA of pembrolizumab?

A

Binds to PD-1 on T cells to block PD-L1 on cancer cells from binding to PD-1 – PD-L1 binding to PD-1 inhibits T cell activation so that cancer cells can evade immune response (inhibited by Pembrolizumab)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is pembrolizumab administered?

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the Vd of pembrolizumab?

A

~7L - small because it is a protein molecule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the half-life of pembrolizumab?

A

~27 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How long does it approximately take for pembrolizumab to reach Css?

17
Q

How is pembrolizumab cleared?

A

Cleared from circulation through non-specific catabolism (because it is a protein)

18
Q

What are the adverse effects of pembrolizumab?

A
  • Infusion related SEs – rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, fever
  • Fatigue
  • Diarrhoea
  • Nausea
  • Joint pain
  • (Life-threatening) Immune related inflammation on lung, endocrine organs, liver, kidney
  • (Life-threatening) Sepsis
19
Q

What are the contraindications for pembrolizumab?

A
  • Taking corticosteroids or immunosuppressants – stop before starting pembrolizumab (starting afterwards is fine)
  • Pregnancy – may inc miscarriage risk
  • Hx of severe reaction to another antibody therapy eg hypersensitivity
  • Hx of other illnesses – infection, liver/kidney diseases etc (consult dr – risk of opportunistic infection)
20
Q

What is leuprorelin indicated for?

A

Prostate cancer

21
Q

What is the MOA of leuprorelin?

A
  • A synthetic GnRH analogue – acts as agonist at pituitary GnRH receptors
  • Decreases androgen (testosterone) production in testes to minimise stimulation of androgen-sensitive prostate cancer cells so that the cancer cells undergo apoptosis
  • Continuous administration decreases FSH and LH release to suppress androgen synthesis (as compared to intermittent GnRH which increases FSH and LH instead)
22
Q

How is leuprorelin administered?

A

SC or IM as a single-dose long-acting depot (interval can vary – 1, 3 or 4/12)

23
Q

How long does it take for leuprorelin to reach Cmax?

24
Q

How long does it take for leuprorelin to reach Css?

25
What is the Vd of leuprorelin?
Vd ~27L after IV
26
Does leuprorelin bind to plasma proteins?
In-vitro displayed ~45% plasma protein binding
27
How is leuprorelin metabolised?
Degraded proteolytically (potentially by peptidases) into inactive peptides
28
What is the half-life of leuprorelin?
~3h
29
How is leuprorelin excreted?
<5% by urine
30
What are the adverse effects of leuprorelin?
- Local pain and redness at injection site (~10% of cases) - Hot flushes during first few weeks of Tx - Headaches/dizziness - GI disturbances - Altered mood - Hyperglycemia - Decreased libido (may need to take not depending on whether patient is still sexually active)
31
What are the contraindications for leuprorelin?
- Hypersensitivity to Leuprorelin or other GnRH agonists - Pre-existing heart disease - Patients with risk for osteoporosis
32
What are the indications for bicalutamide?
- Prostate cancer - Androgen deprivation therapy – used during initiation of androgen deprivation therapy w an LHRH agonist to reduce the symptoms of tumor flare in metastatic prostate cancer patients - For locally advanced disease – in conjunction w radiation tx or surgery (start bicalutamide first, then see if response is enough to not need further radiation or surgery)
33
What is the MOA of bicalutamide?
- Competitively antagonises androgen receptor - Inhibits nuclear translocation of the androgen receptor and interaction of the androgen receptor response element – impairs cell proliferation and triggers apoptosis in cancer cells - Androgen deprivation decreases prostate growth rate, thus slowing down progression of prostate CA
34
How is bicalutamide absorbed?
Well absorbed orally, food does not affect F
35
Does bicalutamide bind to plasma proteins?
Yes, highly plasma protein bound (racemic mixture 96%, R-bicalutamide >99%)
36
How is bicalutamide metabolised?
Extensively metabolised in the liver, T1/2 ~6 days (R-isomer) - S-isomer (inactive) rapidly cleared by glucuronidation - R-isomer (active) slowly cleared by CYP3A4 hydroxylation, then glucuronidation
37
How is bicalutamide excreted?
Parent drug and metabolites excreted by faeces and urine
38
What are the adverse effects of bicalutamide?
- Hot flushes - Nausea, vomiting - Dec sexual desire/ability (may need to take note of if patient is still sexually active) - Fatigue - Constipation/diarrhoea - Mild swelling of ankles, legs and/or feet
39
What are the contraindications for bicalutamide?
- Women and children - Patients with known hypersensitivity reaction to bicalutamide or any of the excipients